Marianne P. Allen

Array ( [id] => 8866588 [patent_doc_number] => 20130150291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'THERAPEUTIC AGENTS COMPRISING INSULIN AMINO ACID SEQUENCES' [patent_app_type] => utility [patent_app_number] => 13/687776 [patent_app_country] => US [patent_app_date] => 2012-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11968 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13687776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9989445 [patent_doc_number] => 09034646 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-19 [patent_title] => 'Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof' [patent_app_type] => utility [patent_app_number] => 13/684746 [patent_app_country] => US [patent_app_date] => 2012-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10196 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13684746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8854121 [patent_doc_number] => 20130143796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-06 [patent_title] => 'CHIMERIC POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/680986 [patent_app_country] => US [patent_app_date] => 2012-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 24552 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13680986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9875290 [patent_doc_number] => 08962557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-24 [patent_title] => 'Fibroblast growth factor mutants having improved functional half-life and methods of their use' [patent_app_type] => utility [patent_app_number] => 13/669856 [patent_app_country] => US [patent_app_date] => 2012-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 44 [patent_no_of_words] => 33378 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13669856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8821050 [patent_doc_number] => 20130122095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOCHONDRAL DEFECTS' [patent_app_type] => utility [patent_app_number] => 13/667566 [patent_app_country] => US [patent_app_date] => 2012-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 30736 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13667566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9468991 [patent_doc_number] => 08722621 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-13 [patent_title] => 'Stabilized insulin-like growth factor polypeptides' [patent_app_type] => utility [patent_app_number] => 13/664055 [patent_app_country] => US [patent_app_date] => 2012-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 30 [patent_no_of_words] => 12569 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13664055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8670941 [patent_doc_number] => 20130045479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-21 [patent_title] => 'METHODS FOR EVALUATING THE STAGE OF OVARIAN CANCER OR THE SURVIVAL RATE OF AN OVARIAN CANCER PATIENT' [patent_app_type] => utility [patent_app_number] => 13/659834 [patent_app_country] => US [patent_app_date] => 2012-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12569 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13659834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9015577 [patent_doc_number] => 20130230541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'ANTI-IGF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/653843 [patent_app_country] => US [patent_app_date] => 2012-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 18509 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13653843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10090243 [patent_doc_number] => 09127056 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-08 [patent_title] => 'Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)' [patent_app_type] => utility [patent_app_number] => 14/352312 [patent_app_country] => US [patent_app_date] => 2012-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 23 [patent_no_of_words] => 30188 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14352312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767028 [patent_doc_number] => 20130095065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'Methods for Treating Vascular Leak Syndrome and Cancer' [patent_app_type] => utility [patent_app_number] => 13/652203 [patent_app_country] => US [patent_app_date] => 2012-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 22438 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13652203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8671378 [patent_doc_number] => 20130045916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-21 [patent_title] => 'TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF' [patent_app_type] => utility [patent_app_number] => 13/647453 [patent_app_country] => US [patent_app_date] => 2012-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 24286 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13647453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8659092 [patent_doc_number] => 20130039921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-14 [patent_title] => 'Treatment of Inflammatory Skin Disease and Psychiatric Conditions' [patent_app_type] => utility [patent_app_number] => 13/644976 [patent_app_country] => US [patent_app_date] => 2012-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5542 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13644976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9698953 [patent_doc_number] => 20140248638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-04 [patent_title] => 'OXMIF AS A DIAGNOSTIC MARKER' [patent_app_type] => utility [patent_app_number] => 14/350186 [patent_app_country] => US [patent_app_date] => 2012-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 18501 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14350186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628739 [patent_doc_number] => 09346884 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Biological materials related to c-Met' [patent_app_type] => utility [patent_app_number] => 14/347697 [patent_app_country] => US [patent_app_date] => 2012-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 66269 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628739 [patent_doc_number] => 09346884 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Biological materials related to c-Met' [patent_app_type] => utility [patent_app_number] => 14/347697 [patent_app_country] => US [patent_app_date] => 2012-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 66269 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14347697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8648823 [patent_doc_number] => 20130034553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-07 [patent_title] => 'Fusion Polypeptides Capable of Activating Receptors' [patent_app_type] => utility [patent_app_number] => 13/628082 [patent_app_country] => US [patent_app_date] => 2012-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15246 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13628082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9232595 [patent_doc_number] => 08597898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-03 [patent_title] => 'Fusion polypeptides capable of activating receptors' [patent_app_type] => utility [patent_app_number] => 13/628084 [patent_app_country] => US [patent_app_date] => 2012-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15245 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13628084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8618159 [patent_doc_number] => 20130023471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-24 [patent_title] => 'METHODS TO RESTORE GLYCEMIC CONTROL' [patent_app_type] => utility [patent_app_number] => 13/619495 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16892 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13619495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9869250 [patent_doc_number] => 08957023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-17 [patent_title] => 'Methods for making proteins containing free cysteine residues' [patent_app_type] => utility [patent_app_number] => 13/616608 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 41927 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13616608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9323404 [patent_doc_number] => 08658423 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-25 [patent_title] => 'Insulin-like growth factor II (IGF-II) binding factors' [patent_app_type] => utility [patent_app_number] => 13/618064 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 16677 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13618064 [rel_patent_id] =>[rel_patent_doc_number] =>)